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Objective: The goal of this project was to identify genetic variants associated with abdominal aortic aneurysms (AAAs).
Methods: A genome wide association study was carried out using pooled DNA samples from 123 AAA cases and 112 controls
matched for age, gender, and smoking history using Affymetrix 500K single nucleotide polymorphism (SNP) arrays
(Affymetrix, Inc, SantaClara, Calif). The difference inmean allele frequency between cases and controlswas calculated for each
SNP and used to identify candidate genomic regions. Association of candidate SNPs with AAA was confirmed by individual
TaqMan genotype assays in a total of 2096 cases and controls that included an independent replication sample set.
Results: A genome wide association study of AAA cases and controls identified a candidate AAA-associated haplotype on
chromosome 3p12.3. By individual genotype analysis, four SNPs in this regionwere significantly associatedwith AAA in cases
and controls from the original study population. One SNP in this region (rs7635818) was genotyped in a total of 502 cases
and 736 controls from the original study population (P  .017) and 448 cases and 410 controls from an independent
replication sample (P  .013; combined P value  .0028; combined odds ratio [OR]  1.33). An even stronger association
with AAAwas observed in a subset of smokers (391 cases, 241 controls, P .00041,OR 1.80), which represent the highest
risk group for AAA. The AAA-associated haplotype is located200 kbp upstream of the CNTN3 gene transcription start site.
Conclusion: This study identifies a region on chromosome 3 that is significantly associated with AAA in 2 distinct study
populations. ( J Vasc Surg 2009;49:1525-31.)
Clinical Relevance: Genotype data can be used to identify individuals at increased genetic risk for AAA. Ultimately this
genetic information may lead to improved diagnosis and better understanding of the pathophysiology of AAAs.Abdominal aortic aneurysms (AAAs) are a leading
cause of death in the elderly, usually from aneurysm rup-
ture.1,2 Many patients with AAAs are undiagnosed. The
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since surgical treatments to repair aneurysms before they
rupture are safe and effective. The most important risk
factors for AAAs are old age, male gender, smoking, and
family history of AAA. The underlying causes of aneurysm
formation are not known. Investigations into the patho-
physiology of AAA have focused on remodeling of the
extracellular matrix and inflammation as important mecha-
nisms in AAA formation.3-8
Family and epidemiologic studies demonstrate a sub-
stantial genetic risk for AAA.4,9 AAA is a complex disease
with risk influenced by an unknown number of genes that
act in combination with environmental factors such as
smoking. Identifying specific genetic factors that are asso-
ciated with AAA would be extremely useful in developing
improved methods to diagnose and treat the disease. While
a number of candidate gene association studies that exam-
ined genes selected on the basis of their predicted role in
AAA have been reported,4,9 none of these studies have
conclusively identified any AAA-associated variants. Previ-
ously, whole genome linkage analyses using family-based or
affected-relative-pair methods identified two AAA-associated
genetic loci designated as the AAA1 (on 19q13) and AAA2
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genetic variants in these regions have not yet been identified.
Another approach to identifying genetic variants asso-
ciated with complex disease is a genome wide association
study (GWAS) in unrelated groups of cases and matched
controls, preferably using large numbers of genetic mark-
ers. The genetic markers of choice for GWAS are single
nucleotide polymorphisms (SNPs). Most SNPs are bi-allelic,
stable in the genome, and easily assayed. Several million
common SNPs have been identified. In a typical GWAS,
the majority of SNP alleles that are assayed have no known
functional effects (eg, they do not alter protein coding
information). However, because genetic variants that are
physically close in the genome will generally be inherited
together (are in linkage disequilibrium, linkage disequilib-
rium [LD]), SNPs that are nearby a functional genetic
variant can serve as markers for the functional variant. A
previous GWAS identified a genetic variant on chromo-
some 9 that is associated with a moderate increase in AAA
risk.12
We carried out a case-control GWAS using a DNA
pooling strategy that identified a candidate AAA-associated
genomic region on chromosome 3p12.3. An SNP within




Geisinger vascular clinic (GVC) samples. The pri-
mary case and control groups consisted of patients enrolled
through the Geisinger Clinic Department of Vascular Sur-
gery. Patients had a diagnosis of AAA (defined as an aortic
diameter of 3 cm or greater) as determined by abdominal
imaging study and confirmed by an attending vascular
surgeon. Controls were patients of the same clinic that were
AAA-free, based on evaluation by a vascular surgeon of an
abdominal imaging study carried out within the preceding
5 years. At enrollment, all participants provided a blood
sample for DNA extraction, completed a questionnaire that
collected information about smoking history, family history
of AAA, and other information potentially related to AAA
risk factors. Subjects also gave permission to extract clinical
and demographic information from their electronic medi-
cal record (EMR). Characteristics of the GVC subjects are
provided in Supplementary Table I, online only.
Geisinger MyCode samples. A secondary control
group was obtained through the Geisinger MyCode
Project, a population cohort of Geisinger Clinic primary
care patients recruited for genomic studies. Enrolled par-
ticipants agreed to provide blood samples for genomic
research and permission to extract clinical and demographic
data from their EMR. For this study, DNA samples from
442 MyCode participants were randomly selected from a
collection of DNA samples from more than 5000 patients
and were matched for age distribution and gender to the
GVC cases, and excluded patients with a diagnosis of AAA
in their EMR.Replication sample set. These samples consisted of
453 AAA cases and 418 controls that were recruited from
Belgium, Canada, and the USA. These samples have been
used in other genetic studies of AAA, and have been
described previously.12
Appropriate institutional approvals were obtained for
use of human subjects in this research.
DNA purification. DNA was purified from EDTA-
anti-coagulated blood using a Qiagen BioRobot M48
Workstation and MagAttract DNA Blood Midi M48 kit
(Qiagen, Valencia, Calif). The yield and purity of DNA was
determined by measuring the absorbance at 260 and 280
nm using a Nanodrop spectrophotometer (ThermoFisher
Scientific, Waltham, Mass).
Genome wide association study. We carried out an
initial GWAS of AAA cases and controls using a DNA
pooling strategy similar to that used in previous stud-
ies.13-16 A flow-chart that summarizes the GWAS strategy
is in Supplemental Fig 1, online only. Three identical DNA
pools were generated independently from DNA samples of
123 cases or 112 controls (a total of 6 pools) from the GVC
samples. Cases and controls were matched for male/female
ratio and age; all had a smoking history of 20 years. The
characteristics of the subjects used for the GWAS are shown
in Supplementary Table II, online only. To create the DNA
pools, 100 ng of DNA from each subject was combined and
then precipitated at 20oC by adding 0.1 volume of 3 M
sodium acetate, pH 5.2, and 2.5 volumes of ethanol. The
DNA was collected by centrifugation, washed with 70%
ethanol, and air-dried. The dried pellets were dissolved in
water at a final concentration of 50 ng/mL.
The six DNA pools were hybridized separately to Af-
fymetrix SNP arrays using the GeneChip Mapping 500K
Manual Protocol (Affymetrix, Inc, Santa Clara, Calif).
Pooled DNA (250 ng/array) was digested with Nsp I or
Sty I and ligated to adapters that recognize overhangs
generated by the restriction enzymes. Oligonucleotides
that recognize the adapter sequences were used as primers
to amplify the adapter-ligated DNA fragments. The ampli-
fied DNA was fragmented, labeled, and hybridized to
GeneChip Human Mapping 250K Nsp and 250K Sty
arrays (Affymetrix, Inc) for 18 hours at 47oC. After hybrid-
ization, the chips were washed and stained using an FS-450
mapping 500Kv1-450 fluidics workstation (Affymetrix,
Inc). The arrays were scanned using the GeneChip Scanner
Model 3000 7G. The raw data were analyzed using the
Affymetrix GeneChip Operating Software (GCOS), version
1.4.0.036, andGeneChipGenotyping Analysis Software, ver-
sion 4.1.026 (GTYPE).
The relative frequencies of the two alleles for each SNP
were determined from the hybridization signals. Only the
perfect match probe signals were used in the allele fre-
quency calculation. To identify SNPs with a high measure-
ment variance, the intra-group coefficient of variation (CV)
of the allele frequency for each SNP was calculated. SNPs
with a CV 0.1 in either the case or control group were
discarded. For the remaining 306,330 SNPs, the difference
in mean allele frequency between cases and controls was
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difference between cases and controls for each SNP were
also calculated.
Candidate SNPs for follow-up studies were chosen
from genomic regions that contained multiple SNPs with
highest case-control allele frequency differences. This was
based on the assumption that the high density of SNPs on
the arrays (median distance between SNPs on the arrays is
2.5 kb) would reveal multiple SNPs in LD with the genetic
variants contributing to the disease. To identify such re-
gions, the SNP allele frequency difference data were sorted
by physical position on each autosomal chromosome. Roll-
ing sums of the relative allele frequency differences of five
adjacent SNPs or sums of the –log10 transformed P values
of the SNP allele frequency differences of five adjacent
SNPs along each chromosome were calculated.
Individual genotype analysis. Individual genotype as-
says were performed using the Applied Biosystems (Foster
City, Calif) 7500 Fast Real-Time polymerase chain reaction
(PCR) System and the standard protocol for the MicroAmp
Fast Optical 96-well reaction plate format (Affymetrix, Inc).
PCR amplification was carried out in a 10 L reaction using
10 ng of genomic DNA, TaqMan Genotyping Master
Mix, TaqMan SNP Genotyping Assay probes (Applied Bio-
systems), and DNase-free water. Assay conditions were as
follows: pre-read hold at 60°C for 30 seconds, fluorescence
recording; 1 cycle at 95°C for 10 minutes to activate
AmpliTaq Gold DNA Polymerase (Affymetrix, Inc); 40
cycles of 95°C for 15 seconds and 60°C for 1 minute
followed by a fluorescence recording after each cycle; and a
hold at 60°C for 30 seconds followed by an endpoint
fluorescence recording. Data were analyzed using the 7500
Fast Sequence Detection System Software version 1.4 (Ap-
plied Biosystems), with background fluorescence subtrac-
tion and automatic allele calling. For SNP rs7635818, the
genotype call rates were 99.9% with the Geisinger Clinic
DNA samples and 98.8% with the replication samples.
Contactin-3 transcript assay. Aortic tissue was ho-
mogenized in Trizol reagent (Invitrogen, Carlsbad, Calif)
and total ribonucleic acid (RNA) was extracted following
the standard protocol. Mononuclear cells were obtained
from blood samples collected in Cell Preparation Tubes
with Citrate (BD Diagnostics, Franklin Lakes, NJ). RNA
was isolated using QIAshredder spin columns and RNeasy
kits (Qiagen, Valencia, Calif). Yield and quality of RNA
were determined by measuring the absorbance at 260 nm
and 280 nm.
Total RNA was used as a template for cDNA synthesis
in a reaction that contained the following: 2 g RNA, 4 l
of 10X Mg free buffer (Promega, Madison, Wis), 5 mM
MgCl2(Promega, Madison, Wis), 5 M random hexamers,
1 mM dNTPs, 2 l Superscript II RT (Invitrogen), and
PCR grade water to a final volume of 40 l. Reaction
conditions were 25°C for 10minutes, 50°C for 50minutes,
70°C for 15 minutes followed by a 4°C hold.
cDNAs were used as templates for PCR amplification of
CNTN3 transcripts using JumpStart Taq DNA Polymerase
(Sigma, St Louis, Mo). The standard protocol was used,but with the addition of MgCl2 to a final concentration of
15 mM. Primers for the CNTN3 gene were designed using
PrimerQuest (Integrated DNA Technologies, Coralville,
Iowa). Primer pairs used were: forward 5’ – TGCCCTTG-
GAAATCCCATACCTCA – 3’ and reverse 5’ – TGTC-
CTCCACGGCTATTTCCACAT – 3’ (predicted product
size of 251 bp); and forward 5’ – ACAGACACAACAGC-
CCAACTCTCT – 3’ and reverse 5’ – GGCGGAAAG-
CAACAACATACCCAA – 3’ (predicted product size of
397 bp). PCR amplification conditions were 1 minute at
94°C followed by 35 cycles of 94°C for 1minute, 55°C for 1
minute, and 72°C for 30 seconds, followed by a final exten-
sion at 72°C for 5 minutes and a 4°C hold. Products were
analyzed on 1% agarose gels and stained with ethidium
bromide.
Statistical analyses. Genotype data were analyzed us-
ing Helix Tree Software, version 6.4 (Golden Helix, Inc,
Bozeman, Mont). Analyses included calculations of devia-
tion fromHardy-Weinberg equilibrium, linkage disequilib-
rium, and genetic association. P values for genetic associa-
tion were calculated using recursive partitioning with case/
control selected as a categorical dependent variable and
genotype as the independent variable. The data were also
analyzed assuming a dominant model of genetic associa-
tion, which tests the association of having at least oneminor
allele vs having no copies of the minor allele. Both ap-
proaches yielded essentially identical results. Uncorrected P
values are reported.
Power calculations were performed using the Genetic
Power Calculator.17 We assumed that the polymorphism
and the disease locus were in complete LD and had the
same allele frequencies. Power was calculated for different
model parameters. Assuming a disease prevalence of 0.05
and risk allele frequency of 0.4, the Geisinger Clinic sample
size of 502 cases and 748 controls had an 80% power to
detect a susceptibility locus with a genotypic relative risk
(GRR) of 1.42 for a dominant genetic model at a signifi-
cance level of 0.1. The combined data set of 995 cases
and 1154 controls could detect a dominant disease locus
with a GRR of 1.34 with 80% power at a significance level
of 0.05.
RESULTS
GWAS identifies a variant on 3p12.3 associated
with AAA. As the first part of a multi-stage approach to
identify AAA-associated genetic variants, we carried out a
GWAS using a subset of GVC case and control DNA
samples. Relative SNP allele frequencies in triplicate pools
of 123 case and 112 control samples were determined using
Affymetrix 500K SNP arrays. (See Supplementary Fig 1,
online only, for additional details on the GWAS.) Criteria
for prioritizing candidate SNPs included a combination of
absolute case-control SNP allele frequency differences, t
test P values of SNP allele frequency differences, and phys-
ical clustering of SNPs with allele frequency differences.
Twenty genomic regions on 13 autosomal chromo-
somes that contained clusters of SNPs with significant allele
frequency differences between the case and control groups
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assay in a sample consisting of 550 GVC cases and controls.
A region on chromosome 3p12.3 showed the strongest
association with AAA, and was selected for further analysis,
as described in the following sections.
Validation of results through individual SNP geno-
typing. To conditionally validate the association of this
genomic region with AAA, 10 SNPs in this region were
genotyped in a total of 502 GVC cases and 296 control
samples. Four SNPs, including rs7635818, were signifi-
cantly associated with AAA (Fig 2). The AAA-associated
SNPs are contained within a haplotype block in the
HapMap CEU (Caucasians of European descent from Utah)
population (Fig 2) and were in strong LD in the GVC case
and control samples (D’ 0.98) (Supplementary Fig 2,
online only). SNP rs7635818 was genotyped in an addi-
tional set of 442 controls obtained from the Geisinger
MyCode population that were matched to the GVC case
samples for age and gender. In the combined Geisinger
Fig 1. Genome wide association identifies a candidate abdominal
aortic aneurysm (AAA)-associated region on chromosome 3p12.3.
A, The vertical arrow indicates a region on chromosome 3 that
contains SNPs with significant allele frequency differences between
AAA cases and controls. The known genes in this region are
indicated below the line with their gene names and accession
numbers. Vertical lines and numbers above the line indicate chro-
mosomal position (in millions of base pairs). B, Transformed P
values of case-control allele frequency differences corresponding to
the region indicated by the thick vertical bar in panel A are shown.
Each point represents the sum of 5 adjacent log10 P values. The
physical map is shown for reference. Note the peak of log10 P
value sums located 200,000 base pairs upstream of the CNTN3
gene.samples, (502 cases and 748 controls) SNP rs7635818genotype was significantly associated with AAA (P .017)
(Table). The AAA-associated allele was C (with G as the
major allele) and its frequency was 0.48 in cases and 0.42 in
controls.
Replication of association in an independent sample
set. To further substantiate the genetic association with
AAA, SNP rs7635818 was genotyped in an independent
set of 453 case and 416 control samples obtained from
Belgium, Canada, and the USA. SNP rs7635818 was sig-
nificantly associated with AAA (P .013) in this replication
Fig 2. Genotype analysis and haplotype structure of the abdom-
inal aortic aneurysm (AAA)-associated region on chromosome
3p12.3. Vertical blue arrows indicate the physical positions of the
10 SNPs from this region that were individually genotyped in 451
cases and 279 controls from the Geisinger Vascular Clinic (GVC)
sample set. The position of the CNTN3 gene is shown. The
inverted red triangle is the HapMap R2 linkage disequilibrium
(LD) plot for the Caucasians of European descent from Utah
(CEU) population (red indicates highest R2 values). The table
shows the reference numbers, map positions, and 2 P values for
AAA association of the genotyped single nucleotide polymor-
phisms (SNPs). The significantly associated SNPs are outlined by
red boxes and lie within a CEU haplotype block characterized by
strong LD.
















.73 .67 .27 .33 .013
All samples 950 cases
1146 controls
.73 .67 .27 .34 .0028
SNP, Single nucleotide polymorphism; AAA, abdominal aortic aneurysm;
N, number.sample (Table I), providing additional evidence that this
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data were analyzed in all samples combined (955 cases and
1154 controls), SNP rs7635818 genotype was significantly
associated with AAA (P  .0028) (Table I). A dominant
genetic model yielded the most significant association be-
tween the SNP genotype and AAA.
Interaction with smoking. Smoking is a strong envi-
ronmental risk factor for AAA disease. Because we had
detailed smoking history data on the GVC case and control
samples, we calculated the association of SNP rs7635818
with AAA in the subset of 391 cases and 241 controls with
a smoking history of20 years, and compared these data to
those for the unstratified GVC cases and controls and the
combined set of all cases and controls. In the combined
sample set, the odds ratio (OR) for association of SNP
rs7635818 with AAA was 1.33 (95% confidence interval
[CI] 1.10-1.61, P  .0014) (Fig 3). In the unstratified
GVC samples, the OR was 1.56 (95% CI 1.15-2.13, P 
.0044), and in the GVC smokers-only samples the OR was
1.80 (95% CI 1.3-2.5, P  .00041). Thus, the association
of SNP rs7635818 with AAA appears to be stronger in
individuals with a history of smoking.
CNTN3 is expressed in AAA and other vascular
tissues. SNP rs7635818 is upstream of the CNTN3
gene, which encodes a lipid-anchored cell adhesion pro-
tein (contactin-3).18 The CNTN3 gene has not been re-
ported previously to be expressed in vascular tissue. To
assay CNTN3 transcripts, RNA extracted from AAA tissue,
control aortic tissue, aortic-occlusive disease (AOD) tissue,
and peripheral blood mononuclear cells from AAA pa-
tients was used to generate cDNAs that were used as
templates for PCR amplification using CNTN3-specific
primers. Products derived from CNTN3 transcripts were
Fig 3. Odds ratios and P values for abdominal aortic aneurysm
(AAA) association of single nucleotide polymorphism (SNP)
s7635818. The graph shows the calculated odds rations (with 95%
confidence intervals [CI]) for all samples combined, the set of all
Geisinger Vascular Clinic (GVC) samples, and the GVC samples
from subjects with 20 or more years of smoking history. The total
sample size and 2 P values are also shown. These values were
calculated using Helix Tree Software (version 6.4; Golden Helix,
Bozeman, Mont), assuming a dominant genetic model. The
dashed vertical line indicates an odds ratio of 1.detected in all the tissues sampled (Fig 4), demonstratingthat the gene is actively expressed in aortic tissue, includ-
ing AAA specimens.
DISCUSSION
We carried out a genome wide association study to
identify genomic variants associated with AAA. A DNA
pooling strategy in conjunction with high density allele
frequency determinations using Affymetrix 500K SNP ar-
rays identified a candidate genomic region on chromosome
3p12.3. To validate the association of this region with
AAA, several SNPs in this region were individually geno-
typed in additional case and control samples. Genetic asso-
ciation was also confirmed in an independent replication
sample set. One SNP in this region, rs7635818, was
genotyped in a total of 2096 case and control samples.
SNP rs7635818 genotype was significantly associated
with AAA, with a 2 P value of .0028 and a calculated OR
of 1.33 (1.10-1.61 95% CI). This is comparable to the
OR of the previously reported AAA-associated SNP on
chromosome 9.10
The Affymetrix chips we used contained probes for
approximately 500,000 common SNPs, which are located
throughout the genome; most do not overlap known
genes. These differ from other gene chips that are used to
measure gene activity or expression. An advantage of a
genome wide association study of the type reported here is
that the outcome is not dependent on a priori assumptions
about the underlying biological mechanisms.
SNP rs7635818 is probably not the genetic variant that
is functionally responsible for increased AAA risk. Rather, it
is likely that this SNP serves as a marker for a functional
genetic variant that increases AAA risk that is in LDwith the
marker SNP. SNP rs7635818 is contained within a haplo-
type block that shows strong LD in the HapMap CEU
population and in the case and control groups used for this
study. Our genetic mapping studies showed the AAA-
associated haplotype block that contains SNP rs7635818
to span approximately 30 kb of genomic DNA sequence.
Fig 4. Expression of contactin-3 transcripts in aortic tissue. Total
ribonucleic acid (RNA) isolated from abdominal aortic aneurysm
(AAA) tissue, control (normal) aortic tissue, aortic occlusive dis-
ease tissue (AOD), or peripheral bloodmononuclear cells (PBMC)
from patients with AAA were used as templates for reverse tran-
scriptase and polymerase chain reaction (PCR) amplification using
contactin-3 specific primers. The products were resolved on an
agarose gel and stained with ethidium bromide. The expected
position of the contactin-3-specific product is indicated by the
arrow. Two independent samples of each type were analyzed.
Identical results were obtained with a different pair of contactin-
3-specific PCR primers (data not shown). Con, xxx.This region does not overlap any known protein coding
JOURNAL OF VASCULAR SURGERY
June 20091530 Elmore et algenes, but is approximately 200 kb upstream of the tran-
scription start site for the CNTN3 gene. (The next nearest
genes are PDZRN3 and ROBO2, which are approximately
1.3 and 2.2 million bp away, respectively.) There are no
non-synonymous SNPs in CNTN3 reported in public da-
tabases that change the predicted structure of activity of the
CNTN3 gene product. Together, these results suggest that
the functional genetic variant has a regulatory function.
Because it lies upstream of the CNTN3 gene, where se-
quence motifs that regulate CNTN3 gene activity are ex-
pected to be located, our working hypothesis is that the
functional variant is in the upstream regulatory region of
the CNTN3 gene. The product of the CNTN3 gene is a
lipid-anchored cell adhesion protein that had been previ-
ously shown to be expressed in the central nervous sys-
tem.18 In support of this hypothesis, we found that the
CNTN3 transcript is readily detected in aortic tissue, in-
cluding both normal and AAA tissue. Although this
genomic region contains consensus DNA binding sites for
known transcription factors, no studies to date have exam-
ined the effects of sequence variants in the AAA-associated
haplotype block marked by SNP rs7635818 on CNTN3
expression. Unfortunately, the limited number of high
quality tissue samples that were available from AAA and
risk-matched normal aortas did not allow a quantitative
analysis of contactin-3 mRNA levels to determine whether
the genetic variant altered expression of the gene. More-
over, since the cellular and biochemical changes that initi-
ate AAA formation, the events most likely to be influenced
by genes that increase AAA risk, occur well before the
lesions are diagnosed clinically and repaired, it is not feasi-
ble to obtain biological samples from humans to test this
hypothesis directly.
A dominant genetic model yielded the most significant
association between SNP rs7635818 genotype and AAA.
This would be consistent with the existence of a genetic
variant in the CNTN3 promoter that affects contactin-3
expression, either constitutively or in response to regula-
tory signals. Regulation of contactin-3 expression in vascu-
lar tissue has not been investigated.
A potentially important suggestive finding from the
study was that the genetic risk associated with SNP
rs7635818 was greater in individuals with a history of
smoking. Smoking is a strong non-genetic risk factor for
AAA. These findings suggest a gene-environment interac-
tion that influences AAA risk. Because smoking history data
were only available on the subjects recruited from the
Geisinger Vascular Clinic, there were not sufficient num-
bers of non-smoking cases or controls to carry out an
independent calculation of genetic risk in non-smokers. It
is also interesting to note that the initial GWAS was carried
out using only cases and controls with a history of smoking.
This might explain why a relatively underpowered GWAS
identified this genomic region. The matching for smoking
history in the GWAS and demonstration of genetic associ-
ation in the smoking sub-group also rules out the possibil-
ity that the observed association is related to smoking or a
related characteristic (eg, smoking addiction).These considerations also highlight the value of DNA
samples from thoroughly characterized subjects for genetic
association studies. A sufficient breadth of data allows for
careful matching of cases and controls for known risk
factors and the ability to examine interactions among ge-
netic and non-genetic risk factors. It is also important to
note that the GVC controls were screened to eliminate
patients with undiagnosed AAA, which has been estimated
to occur in up to 6% of individuals in the highest risk group,
ie, male smokers over the age of 70 years. This could
explain why the P value for association of SNP rs7635818
with AAA was not as robust in the replication sample set
compared to the Geisinger samples, as these were not as
closely matched for the other risk factors (eg, male gender)
and were not screened for undiagnosed AAA.
The genetic variant reported here has a moderate but
statistically significant association with AAA disease. This
variant and the previously reported SNP on chromosome
9p21 account for only a portion of the genetic risk for AAA.
Studies are ongoing to discover additional AAA-associated
genetic variants. A long-term goal of this research is to use
genetic information to quantify AAA disease risk, probably
through the use of a panel of AAA-associated genetic
variants. This would enable high-risk individuals to be
identified for closer monitoring to detect undiagnosed
AAAs, so that appropriate treatment can be provided in a
timely manner. Knowledge of disease-associated genetic
variants can also provide new insight into disease mecha-
nisms and provide targets for development of novel thera-
pies.19 At the present time, there are no medical treatments
for AAAs. The proximity of this AAA-associated genetic
variant to the CNTN3 gene, for example, should provide
the impetus to study that gene and its product, contactin-3,
in the context of vascular disease.
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